|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These results could be explained by increased disease heterogeneity in the noncataplexy group or by a direct effect of the HLA DQB1*0602 genotype on the clinical expression of narcolepsy.
|
9456467 |
1997 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
The cataplectic narcolepsy differed from non-cataplectic narcolepsy by having more rapid eye movement (REM)-related clinical symptoms (more sleep paralysis and sleep-related hallucination) and sleep disturbances (shorter REM latency), as well as tighter association with HLA DQB1*0602.
|
18388176 |
2008 |
|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Narcolepsy symptom severity varies in a linear manner according to HLA-DQB1*0602 allele status.
|
20120618 |
2010 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
The association between narcolepsy and human leukocyte antigen HLA- DQB1*06:02 has been established elsewhere but remains to be investigated among Saudi Arabian patients with narcolepsy.
|
30187366 |
2019 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
The importance of HLA DQB1*0602 typing in Slovene patients with narcolepsy.
|
12097985 |
2002 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
Human narcolepsy is tightly associated with HLA-DQB1*0602; canine narcolepsy is linked with a DNA segment with high homology with the human immunoglobulin mu-switch segment, and the onset of canine narcolepsy is associated with increased microglial expression of major histocompatibility complex DQ and DR molecules.
|
9363189 |
1996 |
|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Narcolepsy is strongly associated with the HLA DQB1*0602 allele, and its symptoms stem from destruction of hypocretin-secreting neurons in the hypothalamus.
|
22213222 |
2012 |
|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
To quantify T CD4, T CD8 and B lymphocytes in subgroups of patients with narcolepsy and the presence or absence of the HLA-DQB1*0602 allele between groups.
|
17665008 |
2007 |
|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
HLA-DQB1*0602 and HLA DRB1 alleles are closely associated with narcolepsy.
|
18345414 |
2007 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
Increased prevalence of HLA-DQB1*0602, a marker of narcolepsy, was observed in males but not in females with > or =2 SOREMPs.
|
16597649 |
2006 |
|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Clock gene polymorphisms and narcolepsy in positive and negative HLA-DQB1*0602 patients.
|
16125818 |
2005 |
|
Narcolepsy
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
There was no difference in the MX2 expression level between the narcolepsy subjects and the HLA-DQB1 genotype-matched control subjects.
|
18517045 |
2008 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
We decided to test for the presence of several neuron-specific and organ-specific autoantibodies to see if they were present in HLA DQB1*0602-associated or cataplexy-associated narcolepsy or could serve as a serologic marker of the illness.
|
12405606 |
2002 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
These results indicate that HLA-DQB1*0602 homozygosity increases susceptibility to narcolepsy but does not appear to influence disease severity.
|
9459509 |
1998 |
|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In the present study, HLA-DQB1 in 664 Japanese narcoleptic subjects and 3131 Japanese control subjects was examined to determine whether HLA-DQB1 alleles located in trans of DQB1*06:02 are associated with narcolepsy.
|
25256355 |
2015 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1*0602.
|
15683136 |
2004 |
|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our data add further support to the strong association of the HLA-DQB1(∗)06:02 allele with narcolepsy, especially in narcolepsy+cataplexy patients.
|
24157097 |
2013 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
HLA-DQB1*0602 forms a heterodimer with HLA-DQA1*0102 and may act as an antigen presenter to the T cell receptors, resulting in narcolepsy susceptibility.
|
28108192 |
2018 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
HLA DQB1*0602 is found in most individuals with hypocretin-deficient narcolepsy, a disorder characterized by a severe disruption of sleep and wake.
|
21292329 |
2011 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
In this paper, we extend an analysis of the effect of HLA-DQB1 on narcolepsy risk published recently by Tafti et al.
|
25325462 |
2015 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
This diagnosis was defined as narcolepsy associated with cataplexy plus HLA-DQB1*06:02 positivity (no cerebrospinal fluid hypocretin-1 results available) or narcolepsy with documented low (≤ 110 pg/mL) cerebrospinal fluid hypocretin-1 level.
|
23649748 |
2013 |
|
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
Although narcolepsy presents one of the tightest associations with a specific human leukocyte antigen (HLA) (DQB1*0602), there is strong evidence that non-HLA genes also confer susceptibility.
|
16754256 |
2006 |
|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Narcolepsy (hypocretin deficiency), a sleep disorder characterized by sleepiness, cataplexy and rapid eye movement (REM) sleep abnormalities, is tightly associated with HLA-DRB1*1501 (M17378) and HLA-DQB1*0602 (M20432).
|
18820697 |
2008 |
|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This comprehensive genetic study sought to assess variations in CHKB and CPT1B susceptibility genes and HLA-DQB1*06:02 allele status in Turkish patients with narcolepsy and healthy persons.
|
24571861 |
2014 |
|
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of the HLA-DQB1*0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in São Paulo.
|
19506770 |
2009 |